Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ENGN
STRONG SELLREMOVEenGene Therapeutics Inc. · Healthcare · Canada · $114M · Avg Vol: $3M/d
Clinical-stage biotech with zero revenues and high cash burn. Fails the Terry Smith filter of avoiding pre-revenue turnarounds or speculative biotech.
COMPANY DESCRIPTION
enGene Therapeutics Inc. is a clinical-stage biotechnology company developing a novel gene therapy platform for the localized delivery of therapeutics, particularly in oncology and immunology. The company's proprietary non-viral DDX platform is designed for sustained, targeted protein expression directly at the disease site, potentially offering improved safety and efficacy. It positions itself as an innovator in gene therapy, initially focusing on addressing high unmet needs in bladder cancer treatment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| EPS | -0.43 | -1.56 | -1.46 | -2.29 | — |
| Shares | 67.0M | 67.0M | 51.0M | 52.0M | -22.3% |
| Debt | 32.1M | 9.8M | 25.0M | 31.8M | -0.3% |
| Equity | -23.5M | 72.5M | 272.6M | 167.7M | 52.1% |
| Op CF | -17.6M | -24.7M | -48.3M | -99.2M | — |
| Inv CF | -0.2M | -0.3M | -126.0M | -25.1M | — |
| Fin CF | 28.0M | 86.1M | 265.7M | 1.5M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc.(you) | $114M | 8 | STRONG SELL |
| MSLE | Satellos Bioscience Inc. | $119M | 10 | STRONG SELL |
| PMN | ProMIS Neurosciences, Inc. | $97M | 15 | STRONG SELL |
| MIST | Milestone Pharmaceuticals Inc. | $161M | 1 | STRONG SELL |
| OBI.L | Ondine Biomedical Inc. | $101M | 20 | SELL |
| HELP | Cybin D/B/A Helus Pharma | $245M | 6 | STRONG SELL |
| EDSA | Edesa Biotech, Inc. | $61M | 17 | STRONG SELL |
| NGEN | NervGen Pharma Corp. | $244M | 1 | STRONG SELL |
| QNTM.CN | Quantum BioPharma Ltd. | $45M | 2 | STRONG SELL |
| MDNA.TO | Medicenna Therapeutics Corp. | $27M | 1 | STRONG SELL |
Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 35.6%